Biologic therapy: let the Copernican revolution begin

Summary Non‐infectious uveitis can be a potentially sight‐threatening disease. The advent of biologic drugs has represented a Copernican revolution for ocular inflammatory diseases therapies: biologic treatments are a great opportunity for those patients affected by severe, non‐responder, sight threatening uveitis. The availability of such drugs has significantly improved the uveitis outcome. Several publications have reported the efficacy of biologic agents in a progressively larger number of refractory uveitides, suggesting a central role for biologic drugs in selected cases. On the other hand, the medical literature has not provided yet significant numbers and most of the biologic drugs available have been reported in small case series. The anti‐tumor necrosis factor (TNF)‐α is the category with the most consistent medical literature in uveitis and, very recently, Adalimumab has recently obtained the indication for the treatment of non‐infectious posterior, intermediate, pan‐uveitis, representing the first on label biologic agent used in ophthalmology for the therapy of uveal inflammation.